JP Morgan Chase’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.72M | Buy |
+55,000
| New | +$5.27M | ﹤0.01% | 3364 |
|
|
2025
Q4 | – | Sell |
-1,200
| Closed | -$114K | – | 7629 |
|
|
2025
Q3 | $114K | Sell |
1,200
-53,800
| -98% | -$4.95M | ﹤0.01% | 5827 |
|
|
2025
Q2 | $4.79M | Sell |
55,000
-341,700
| -86% | -$29M | ﹤0.01% | 3210 |
|
|
2025
Q1 | $35.6M | Buy |
396,700
+373,100
| +1,581% | +$33.4M | ﹤0.01% | 1507 |
|
|
2024
Q4 | $1.89M | Hold |
23,600
| – | – | ﹤0.01% | 4197 |
|
|
2024
Q3 | $2.12M | Sell |
23,600
-62,900
| -73% | -$5.29M | ﹤0.01% | 3964 |
|
|
2024
Q2 | $6.81M | Buy |
86,500
+38,200
| +79% | +$3.13M | ﹤0.01% | 2794 |
|
|
2024
Q1 | $4.21M | Buy |
48,300
+37,800
| +360% | +$3.23M | ﹤0.01% | 3237 |
|
|
2023
Q4 | $865K | Sell |
10,500
-26,800
| -72% | -$2.04M | ﹤0.01% | 4425 |
|
|
2023
Q3 | $2.92M | Buy |
37,300
+15,200
| +69% | +$1.27M | ﹤0.01% | 3260 |
|
|
2023
Q2 | $1.95M | Buy |
+22,100
| New | +$1.9M | ﹤0.01% | 3562 |
|
|
2022
Q3 | – | Sell |
-50,000
| Closed | -$4.49M | – | 6691 |
|
|
2022
Q2 | $4.49M | Buy |
50,000
+44,900
| +880% | +$4.55M | ﹤0.01% | 2864 |
|
|
2022
Q1 | $566K | Sell |
5,100
-23,500
| -82% | -$2.48M | ﹤0.01% | 4628 |
|
|
2021
Q4 | $2.96M | Sell |
28,600
-64,800
| -69% | -$7.5M | ﹤0.01% | 3508 |
|
|
2021
Q3 | $11.7M | Buy |
93,400
+64,800
| +227% | +$8.39M | ﹤0.01% | 2247 |
|
|
2021
Q2 | $3.55M | Buy |
28,600
+14,600
| +104% | +$1.83M | ﹤0.01% | 3343 |
|
|
2021
Q1 | $1.65M | Sell |
14,000
-19,200
| -58% | -$2.25M | ﹤0.01% | 3858 |
|
|
2020
Q4 | $3.89M | Buy |
33,200
+32,100
| +2,918% | +$3.53M | ﹤0.01% | 3007 |
|
|
2020
Q3 | $113K | Hold |
1,100
| – | – | ﹤0.01% | 4635 |
|
|
2020
Q2 | $101K | Buy |
+1,100
| New | +$105K | ﹤0.01% | 4569 |
|
|
2020
Q1 | – | Sell |
-53,100
| Closed | -$6.02M | – | 5550 |
|
|
2019
Q4 | $6.02M | Sell |
53,100
-78,700
| -60% | -$8.64M | ﹤0.01% | 2547 |
|
|
2019
Q3 | $14.3M | Buy |
+131,800
| New | +$13.8M | ﹤0.01% | 1845 |
|
|
2019
Q2 | – | Sell |
-98,000
| Closed | -$8.93M | – | 5902 |
|
|
2019
Q1 | $8.93M | Sell |
98,000
-181,400
| -65% | -$16.2M | ﹤0.01% | 2153 |
|
|
2018
Q4 | $25.4M | Buy |
279,400
+222,500
| +391% | +$20.8M | 0.01% | 1296 |
|
|
2018
Q3 | $5.6M | Buy |
56,900
+20,000
| +54% | +$1.85M | ﹤0.01% | 2657 |
|
|
2018
Q2 | $3.16M | Hold |
36,900
| – | – | ﹤0.01% | 3047 |
|
|
2018
Q1 | $2.96M | Sell |
36,900
-14,800
| -29% | -$1.22M | ﹤0.01% | 2998 |
|
|
2017
Q4 | $4.17M | Buy |
51,700
+29,800
| +136% | +$2.39M | ﹤0.01% | 2824 |
|
|
2017
Q3 | $1.7M | Buy |
+21,900
| New | +$1.82M | ﹤0.01% | 3246 |
|
|
2017
Q2 | – | Sell |
-53,000
| Closed | -$4.27M | – | 5105 |
|
|
2017
Q1 | $4.27M | Buy |
+53,000
| New | +$4.14M | ﹤0.01% | 2540 |
|
|
2016
Q4 | – | Sell |
-6,262
| Closed | -$541K | – | 5076 |
|
|
2016
Q3 | $541K | Sell |
6,262
-17,500
| -74% | -$1.52M | ﹤0.01% | 3377 |
|
|
2016
Q2 | $2.06M | Buy |
+23,762
| New | +$1.92M | ﹤0.01% | 2789 |
|
|
2015
Q4 | – | Sell |
-35,000
| Closed | -$2.34M | – | 4754 |
|
|
2015
Q3 | $2.34M | Hold |
35,000
| – | – | ﹤0.01% | 2653 |
|
|
2015
Q2 | $2.59M | Hold |
35,000
| – | – | ﹤0.01% | 2760 |
|
|
2015
Q1 | $2.73M | Sell |
35,000
-1,123,400
| -97% | -$85.1M | ﹤0.01% | 2715 |
|
|
2014
Q4 | $83.6M | Buy |
1,158,400
+825,000
| +247% | +$57.3M | 0.02% | 711 |
|
|
2014
Q3 | $20.7M | Buy |
+333,400
| New | +$21.2M | ﹤0.01% | 1425 |
|
Other funds holding MDT
VCM
VPM
JP Morgan Chase's MDT Position: Q1 2026 in Review
JP Morgan Chase reduced its Medtronic (MDT) stake by 4.9% in Q1 2026, selling an estimated $253M and leaving 50,973,541 shares worth $4.37B. The position accounts for 0.28% of the portfolio, ranked #76.
JP Morgan Chase first reported a position in MDT in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.15B in Q4 2025. 2,230 funds tracked by Wall St. Rank hold MDT as of Q1 2026.
- JP Morgan Chase held 50,973,541 shares of Medtronic worth $4.37B as of Q1 2026.
- JP Morgan Chase sold 2,643,153 Medtronic shares in Q1 2026, an estimated $253M.
- Medtronic made up 0.28% of JP Morgan Chase's portfolio in Q1 2026, its #76 holding.
- JP Morgan Chase first reported a position in Medtronic in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Medtronic position peaked at $5.15B in Q4 2025.
- 2,230 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.